Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

aus nature pharmaceuticals pty ltd - lycopersicon esculentum, quantity: 250 mg (equivalent: lycopersicon esculentum, qty 2.5 g; equivalent: steroidal alkaloids calculated as solanine, qty 0.025 mg); cysteine hydrochloride, quantity: 225 mg; rosa rugosa, quantity: 18.75 mg (equivalent: rosa rugosa, qty 187.5 mg); curcuma longa, quantity: 40 mg (equivalent: curcuma longa, qty 800 mg) - capsule, hard - excipient ingredients: microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; purified water; gelatin; titanium dioxide; amaranth; brilliant blue fcf; tartrazine - may assist in lightening skin at the production level. may assist in the reduction of melanin production. may help defend existing skin against uv damage. may help to defend newly produced skin with uv barriers. may promote collagen synthesis for a more youthful and full appearance. may assist in lightening age spots may assist in lightening freckles may assist in sun protection which in turn may assist with anti ageing and photo ageing. may assist with skin whitening, lightening and evening of skin tone. may protect and boost certain biomolecules.

Malta - anglès - Medicines Authority

vale pharmaceuticals limited 3 anglesea street, clonmel, co. tipperary, e91 d6c5, ireland - clopidogrel - film-coated tablet - clopidogrel 75 mg - antithrombotic agents

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance pharmaceuticals ltd - doxycycline hyclate - oral tablet - 20mg

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - bumetanide 1mg;   - tablet - 1 mg - active: bumetanide 1mg   excipient: agar copovidone hydrated silica lactose monohydrate magnesium stearate maize starch polysorbate 80 purified talc - indicated for the treatment of oedema, particularly that associated with congestive heart failure, hepatic and renal diseases including the nephrotic syndrome and acute pulmonary oedema.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - clozapine 200mg;   - tablet - 200 mg - active: clozapine 200mg   excipient: lactose monohydrate magnesium stearate microcrystalline cellulose povidone purified water sodium starch glycolate - the use of clozapine is indicated in the treatment of resistant schizophrenic patients only, i.e. schizophrenic patients who are non-responsive to or intolerant of classical antipsychotics. non-responsiveness is defined as a lack of satisfactory clinical improvement despite the use of adequate doses of at least two marketed antipsychotics prescribed for adequate durations. intolerance is defined as the impossibility of achieving adequate clinical benefit with classical antipsychotic drugs because of severe and untreatable neurological adverse reactions (extrapyramidal side effects or tardive dyskinesia).

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

link pharmaceuticals ltd - foscarnet sodium hexahydrate 24 mg/ml - solution for infusion - 24 mg/ml - active: foscarnet sodium hexahydrate 24 mg/ml - treatment of cytomegalovirus (cmv) retinitis in patients with acquired immunodeficiency syndrome (aids). treatment of acyclovir resistant herpes simplex virus (hsv) infections in immunocompromised patients. the safety and efficacy of foscavir for the treatment of other hsv infections (e.g. retinitis, encephalitis); congenital or neonatal disease; or hsv in immunocompetent individuals has not been established.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - fusidic acid 1%{relative} - eye drops, solution - 1% w/w - active: fusidic acid 1%{relative} excipient: benzalkonium chloride carbomer disodium edetate dihydrate mannitol sodium hydroxide water for injection - fucithalmic® is indicated for the topical treatment of bacterial eye infections where the organism is sensitive to the antibiotic. these may include: bacterial conjunctivitis, blepharitis, sty, and keratitis.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - glucagon hydrochloride 1mg (recombinant);  ;   - solution for injection - 1 mg - active: glucagon hydrochloride 1mg (recombinant)     excipient: lactose monohydrate water for injection - therapeutic treatment of severe hypoglycaemic reactions, which may occur in the management of diabetic patients receiving insulin or oral hypoglycaemic agents. to prevent the occurrence of secondary hypoglycaemia, oral carbohydrate should be given to restore the hepatic glycogen when the patient has responded to the treatment. the mechanism and hence treatment of sulfonylurea-induced hypoglycaemia differs from that of severe insulin-induced hypoglycaemia in some important ways. consciousness should preferably be restored by the administration of intravenous glucose. if glucagon is used due to the unavailability of intravenous glucose (e.g. before reaching a hospital) care should be taken to protect against secondary hypoglycaemia with constant monitoring of the patient's blood sugar level by medical personnel. subsequent administration of intravenous glucose may be required.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - insulin zinc suspension, crystalline, bovine 100 iu/ml - solution for injection - 100 iu/ml - active: insulin zinc suspension, crystalline, bovine 100 iu/ml

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - insulin zinc suspension, crystalline, bovine 100 iu/ml - solution for injection - 100 iu/ml - active: insulin zinc suspension, crystalline, bovine 100 iu/ml